Jack W. Schuler, a director and 10% owner of Biodesix Inc (NASDAQ:BDSX), filed a Form 4 on November 12, 2026, disclosing a purchase of 100,000 shares of common stock on November 10, 2026, through the Jack W. Schuler Living Trust.

Key Highlights

  • Purchase date: 100,000 shares of Biodesix common stock were acquired on November 10, 2026.
  • Weighted average price: The reported per-share price was $10.0199, representing a weighted average across multiple transactions ranging from $9.655 to $10.25, inclusive.
  • Acquiring vehicle: The shares were purchased indirectly through the Jack W. Schuler Living Trust, of which Schuler is the sole trustee.
  • Post-transaction holdings via Living Trust: Following the purchase, the Living Trust beneficially owned 655,810 shares of common stock.
  • Separate indirect holding: The filing also reports 1,800,000 shares held indirectly through the Jack W. Schuler 2026 GRAT, for which Schuler is also the sole trustee.
  • Reporting person roles: Schuler is identified in the filing as a Director, 10% Owner, and Emeritus Director.

Schuler Living Trust Acquires Biodesix Common Stock in Open-Market Purchases

According to the Form 4 filed with the SEC on November 12, 2026, Jack W. Schuler, acting through the Jack W. Schuler Living Trust, purchased 100,000 shares of Biodesix Inc common stock on November 10, 2026. The transaction code reported is "P," indicating an open-market purchase. The weighted average price per share was $10.0199, and the filing notes that the shares were acquired in multiple transactions at prices ranging from $9.655 to $10.25, inclusive.

The filing states that Schuler, as the sole trustee of the Jack W. Schuler Living Trust, indirectly beneficially owned 655,810 shares following the reported transaction. Separately, the filing discloses that 1,800,000 shares of common stock are held indirectly through the Jack W. Schuler 2026 GRAT, for which Schuler is also identified as the sole trustee. No direct holdings of common stock are reported, and no derivative securities transactions appear in Table II.

The filing was signed by Robin H. Cowie as Attorney-in-Fact for Jack Schuler on November 12, 2026. The reporting person undertakes, according to the filing, to provide full information regarding the number of shares purchased at each separate price within the stated range upon request by the issuer, any security holder, or SEC staff.

What Was Disclosed

The filing disclosed an indirect purchase of 100,000 Biodesix common shares on November 10, 2026, at a weighted average price of $10.0199, through the Jack W. Schuler Living Trust, resulting in 655,810 shares beneficially owned by that trust following the transaction.